NCT04907253View on ClinicalTrials.gov

Quercetin in Coronary Artery By-pass Surgery

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

June 4, 2021

Primary Completion Date

December 1, 2023

Study Completion Date

September 1, 2025

Conditions

Coronary Artery Disease

Interventions

DRUG

Quercetin

500 mg twice daily

DRUG

Placebo

twice daily

Trial Locations (1)

H1T 1C8

Montreal Heart Institute, Montreal

All Listed Sponsors

lead

Montreal Heart Institute

OTHER